Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerativecolitis (UC). Materials and Methods: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. Results: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12–81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). Conclusion: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.
Abstract
Purpose: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerativecolitis (UC). Materials and Methods: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. Results: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12–81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). Conclusion: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.
참고문헌 (21)
- Lee HJ, "Longterm clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mildto-moderate ulcerative colitis", Hepatogastroenterology, 59, pp.1415~1420 (2012)
- Park SJ, "Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives", World J Gastroenterol, 20, pp.11525~11537 (2014)
- 최창환, "궤양성 대장염 치료 가이드라인", 대한소화기학회지, 59(2), pp.118~140 (2012), 대한소화기학회
- 김은수, "Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics", Gut and Liver, 4(1), pp.1~14 (2010), 거트앤리버 발행위원회
- Saibeni S, "Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?", Expert Rev Gastroenterol Hepatol, 8, pp.949~962 (2014)
- Harris DM, "Some properties of beclomethasone dipropionate and related steroids in man", Postgrad Med J, 51(Suppl 4), pp.20~25 (1975)
- Dignass A, "The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management", J Crohns Colitis, 4, pp.28~62 (2010)
- Levine DS, "Coating of oral beclomethasone dipropionate capsules with cellulose acetate phthalate enhances delivery of topically active antiinflammatory drug to the terminal ileum", Gastroenterology, 92, pp.1037~1044 (1987)
- Fascì Spurio F, "Oral beclomethasone dipropionate: a critical review of its use in the management of ulcerative colitis and Crohn’s disease", Curr Clin Pharmacol, 7, pp.131~136 (2012)
- Lewis JD, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis", Inflamm Bowel Dis, 14, pp.1660~1666 (2008)
- Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study", N Engl J Med, 317, pp.1625~1629 (1987)
- 최재혁, "Old Age at Diagnosis Is Associated With Favorable Outcomes in Korean Patients With Inflammatory Bowel Disease", Intestinal research, 13(1), pp.60~67 (2015), 대한장연구학회[DOI]
- Silverberg MS, "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology", Can J Gastroenterol, 19(Suppl A), pp.5A~36A (2005)
- Satoshi Yamada, "Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis", Intestinal research, 13(3), pp.250~258 (2015), 대한장연구학회
- Seong Ran Jeon, "Is Long-Term Therapy With Thiopurines Effective for Maintaining Remission in Patients With Moderate-To-Severe Ulcerative Colitis?", Intestinal research, 13(3), pp.191~192 (2015), 대한장연구학회
- Campieri M, "Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study", Aliment Pharmacol Ther, 17, pp.1471~1480 (2003)
- Rizzello F, "Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study", Aliment Pharmacol Ther, 16, pp.1109~1116 (2002)
- Papi C, "Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates", Dig Dis Sci, 55, pp.2002~2007 (2010)
- Nunes T, "Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice:the RECLICU Study", J Crohns Colitis, 4, pp.629~636 (2010)
- Van Assche G, "Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study", Am J Gastroenterol, 110, pp.708~715 (2015)
- Kim DH, "Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease", Dig Dis Sci, 59, pp.2514~2522 (2014)